Joseph Armstrong, MD
Urology · Salt Lake City, UTNPI 1801258892
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,509 of the $8,744 with a category attached, or 63.0%. 29 manufacturers reported payments, led by Intuitive Surgical at 34.5% of the total. Reporting peaked in 2021 at $4,269 and has fallen 85.2% since, to $633 in 2025.
Across 210 payments — averaging $41.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- Boston Scientific$3K
- 180 Medical, Inc.$492
- Astellas Pharma US Inc$368
- AbbVie$348
- Endo Pharmaceuticals Inc.$219
- plus $1K from 23 others
What the payments were for
- Food & beverage$5,50963%
- Education$3,23537%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 2 | $3,015 |
| Boston Scientific | 85 | $2,887 |
| 180 Medical, Inc. | 17 | $492 |
| Astellas Pharma US Inc | 10 | $368 |
| AbbVie(2 entities) | 18 | $348 |
| Endo Pharmaceuticals Inc. | 12 | $219 |
| Coloplast | 9 | $218 |
| Pfizer | 8 | $166 |
| Endo USA, Inc. | 7 | $140 |
| Axonics, Inc. | 5 | $93 |
| Antares Pharma, Inc. | 6 | $92 |
| Kowa Pharmaceuticals America, Inc. | 5 | $82 |
| Calyxo, Inc. | 1 | $67 |
| Novo Nordisk | 2 | $47 |
| Bayer | 3 | $46 |
| Travere Therapeutics, Inc. | 2 | $45 |
| Teleflex LLC | 2 | $45 |
| Medtronic | 2 | $43 |
| Laborie Medical Technologies Corp. | 1 | $40 |
| Convatec Inc. | 1 | $39 |
| Urovant Sciences Inc | 2 | $39 |
| Sumitomo Pharma America, Inc. | 2 | $39 |
| Procept Biorobotics Corporation | 2 | $37 |
| AstraZeneca | 1 | $35 |
| Urogen Pharma, Inc. | 1 | $27 |
| Progenics Pharmaceuticals, Inc. | 1 | $21 |
| Blue Earth Diagnostics | 1 | $20 |
| Valencia Technologies Corporation | 1 | $19 |
| Olympus America Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,000
- LithoVue$241
How this compares
$8,744 in reported general payments places this provider in the 70th percentile of 96 urology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 221 | $127,037 |
| GemtesaVibegron | 58 | $36,107 |
| Trospium Chloride | 306 | $14,382 |
| Finasteride | 634 | $10,162 |
| Tamsulosin Hcl | 523 | $8,496 |
| Solifenacin Succinate | 56 | $1,726 |
| Potassium Citrate ErPotassium Citrate | 22 | $1,651 |
| Trimethoprim | 15 | $1,189 |
| Dutasteride | 15 | $609 |
| Desmopressin Acetate | 16 | $573 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 44 | $373 |
| Levofloxacin | 112 | $286 |
| Cephalexin | 21 | $264 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 61 | $217 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 12 | $188 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $368 | $127,037221 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $39 | $36,10758 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 96 urology providers in Utah.
Other urology in Salt Lake City
- William BrantSalt Lake City$290K
- Benjamin McCormickSalt Lake City$67K
- Richard MaternSalt Lake City$58K
- Akhil SajiSalt Lake City$49K
- Stephen SummersSalt Lake City$15K
- Jeremy MyersSalt Lake City$15K
- Gary JohnsonSalt Lake City$15K
- Sara LenherrSalt Lake City$12K
- Mitchell BassettSalt Lake City$10K
- Steven LynchSalt Lake City$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.